Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments 

<br/><br/><br/>English[eng] 
<br/><br/><label>ISBN: </label>9783040000000 
<br/><br/><label>Subjects--Topical Terms: </label><br/>non-small cell lung cancer||previously treated patients||phase I/II trial||chemotherapy||docetaxel||S-1||immunotherapy||rechallenge||retrospective analysis||pulmonary pleomorphic carcinoma||prognostic factor||glucose transporter 1||lung cancer||multiple cancers||metastasis||sequencing||mutation||genomic diagnosis||FDG-PET||immune checkpoint inhibitor||PD-1||prognosis||RAD51B methylation||PD-L1 expression||predictive biomarker||PD-1 blockade||interstitial lung disease||pulmonary fibrosis||radiology and other imaging||non-small-cell lung cancer||epidermal growth factor receptor||tyrosine kinase inhibitors||TP53 mutations||responsiveness||targeted therapy||network meta-analysis||stage IIIA-N2||surgery||immune checkpoint inhibitors||biomarker||nonsmall cell lung cancer||HIP1R||PD-L1||RUNX1||methylation||survival||EGFR-TKI||T790M||osimertinib||immune-related adverse events||endocrine disorders||tumor-bearing patients||PD-1 inhibitors||PD-L1 inhibitors||meta-analysis||nivolumab||Expanded Access Program||real-world data||daily practice||prognostic factors||NSCLC||KRAS||DNA polymerase beta||platinum-based first-line||adjuvant chemotherapy||β-catenin||lung neoplasms||nucleotide-diphosphate kinase||recurrence||unresectable||salvage surgery||oligometastasis